TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18622294
Drug: Prophylaxis followed
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis followed by preemptive therapy (ganciclovir for 30 days, then preemptive therapy with virologic monitoring)
Study: 18622294
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy alone (initiated at 100,000 DNA copies/mL whole blood)
Study: 18622294
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (prophylaxis and preemptive therapy)
Study: 16001108
Drug: Alprazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.5 mg b.i.d.)
Study: 12450909
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg elemental Zn/d)
Study: 10614677
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg/day continuously
Study: 10614677
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol 50 mg/day continuously
Study: 7864416
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl infusion (2 micrograms/mL at 4‐10 mL/h)
Study: 7864416
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine via patient-controlled analgesia (IV‐PCA)
Study: 7864416
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl infusion and IV morphine via PCA
Study: 7191614
Drug: E2 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 and E3 orally in doses of 4-8 mg per day for 3 weeks
Study: 7191614
Drug: Gestagen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestagen (1000 mg i.m. injection)
Study: 24113039
Drug: Argatroban (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (200 µg/kg bolus, followed by 350 µg·kg(‐1)·h(‐1) i.v. infusion)
Study: 24113039
Drug: Heparin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (100 U/kg via artery sheaths)
Study: 19906103
Drug: Anti-EGFR monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-EGFR monoclonal antibody
Study: 19906103
Drug: No anti-EGFR
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-EGFR monoclonal antibody (Control)
Study: 17293063
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg L-selenomethionine daily for 6 months
Study: 15510787
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment in addition to routine diabetes treatment
Study: 15510787
Drug: Domperidone treatment
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone treatment in addition to routine diabetes treatment
Study: 15510787
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in addition to routine diabetes treatment
Study: 2979273
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg taken at 18.15 hours after a standard meal at 18.00 hours
Study: 2979273
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg taken at 18.15 hours after a late meal at 22.00 hours
Study: 12719279
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg) plus atorvastatin (10, 20, 40, or 80 mg)
Study: 17560879
Drug: Atorvastatin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10, 20, 40, or 80 mg)
Study: 8994512
Drug: LY293111 (112
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY293111 (112 mg three times daily for seven days)
Study: 1453314
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of chlorpheniramine and cimetidine
Study: 3933202
Drug: Pyoimmunogen vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyoimmunogen vaccine
Study: 31174360
Drug: 75% basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% basal insulin dose
Study: 31174360
Drug: Both trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both trial arms (75% and 100% basal insulin)
Study: 19709787
Drug: 8.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.8 g/d of plant stanols as esters
Study: 16061711
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg 8 hourly for 12 weeks (n = 9)
Study: 16061711
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg 8 hourly for 12 weeks (n = 5)
Study: 1826370
Drug: Diclofenac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (200 mg/day for 4 days)
Study: 6123337
Drug: Lorazepam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 0.05 mg kg‐1
Study: 6123337
Drug: Trimeprazine 3
Normalized name: trimeprazine 30 MG per 5 ML Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimeprazine 3 mg kg‐1
Study: 25018142
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with B blockers
Study: 22459327
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus healthy living skills
Study: 22459327
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus affect regulation training
Study: 19007927
Drug: Wire-guided cannulation
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wire-guided cannulation (WGC) without contrast injection
Study: 19007927
Drug: Conventional cannulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cannulation with contrast injection
Study: 15364317
Drug: Immune modulation
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune modulation therapy (IMT)
Study: 11278160
Drug: 100mcg transdermal
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mcg transdermal estradiol
Study: 11278160
Drug: 50mcg transdermal
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mcg transdermal estradiol
Study: 9549810
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no Tamoxifen treatment)
Study: 8015795
Drug: Experimental dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental dressing (chlortetracycline, aspirin, local anesthetics)
Study: 1257731
Drug: Long-time treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-time treatment with corticosteroids and azathioprine
Study: 1257731
Drug: Short-time treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-time treatment (as short as possible)
Study: 31164148
Drug: 540,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 540,000 IU cholecalciferol followed by monthly supplementation
Study: 31164148
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D oral supplementation
Study: 28739541
Drug: Virtual Advisor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Advisor program (computer-based embodied conversational agent named 'Carmen')
Study: 16827769
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of 0.5% bupivacaine
Study: 16827769
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of 0.9% saline (control)
Study: 15457989
Drug: Timolol-gel alone
Normalized name: timolol Ophthalmic Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol-gel alone
Study: 15457989
Drug: Timolol-gel and
Normalized name: timolol Ophthalmic Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol-gel and latanoprost in combination
Study: 8282290
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg, increased to 10 mg if diastolic BP > 90 mmHg
Study: 2941290
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.i.d. for five days
Study: 18320916
Drug: Albuterol nebulizer
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol nebulizer (2.5 mg)
Study: 17036557
Drug: 1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/d of valacyclovir for 60 days
Study: 15529837
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (7-day outpatient course)
Study: 3526609
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) treatment (6 ng/kg/min, n = 13)
Study: 20484472
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 7.5 g daily
Study: 9759991
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 20 mg b.i.d. for 8 weeks (could be doubled once)
Study: 31686823
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (441 mg and 882 mg)
Study: 31686823
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (441 mg)
Study: 31686823
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (882 mg)
Study: 31686823
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (pooled doses)
Study: 25178517
Drug: Ibrutinib 840
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib 840 mg/day
Study: 24054464
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to monotherapy
Study: 21205110
Drug: Mg-aspartate-hydrochloride (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-aspartate-hydrochloride (n = 27)
Study: 16648513
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy only
Study: 11191541
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (2 microg kg(‐1) min(‐1))
Study: 9170041
Drug: Saline flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline flush after contrast injection
Study: 9170041
Drug: No saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: No saline flush after contrast injection
Study: 1331788
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 and calcium supplementation (1.2 g elemental calcium and 20 micrograms (800 IU) of vitamin D3 daily for 18 months)
Study: 31755300
Drug: Customized meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized meditation program (weekly classes for 2 years)
Study: 26908041
Drug: 2 %
Normalized name: oxygen 2 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 % carbohydrate (L-CHO) beverages
Study: 26908041
Drug: 6 %
Normalized name: oxygen 96 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 % carbohydrate (H-CHO) solutions with 20 g protein
Study: 17644545
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other treatment strategies)
Study: 16648739
Drug: OP‐1 Putty
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP‐1 Putty (3.5 mg OP‐1/g of collagen matrix per side)
Study: 14631136
Drug: ivabradine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 0.25 mg/kg
Study: 10725817
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current (IFC) treatment for palmar psoriasis
Study: 10725817
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current (IFC) treatment
Study: 8840370
Drug: Intramuscular fosphenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular fosphenytoin (480-1500 mg loading doses, 130-1250 mg daily maintenance doses for 3-14 days)
Study: 8840370
Drug: Intravenous fosphenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosphenytoin (1082 +/- 299 mg loading doses, 411 +/- 221 mg daily maintenance doses for 3-14 days)
Study: 8840370
Drug: Intravenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phenytoin sodium (1082 +/- 299 mg loading doses, 422 +/- 197 mg daily maintenance doses for 3-14 days)
Study: 8840370
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous fosphenytoin and phenytoin sodium
Study: 6142005
Drug: Esmolol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (intravenous administration)
Study: 27577513
Drug: Spectral CT
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectral CT imaging (1 ml/kg contrast agent)
Study: 27577513
Drug: Conventional CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CT imaging (120 kVp, 1 ml/kg contrast agent)
Study: 17230596
Drug: Fingolimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25 mg orally
Study: 17230596
Drug: Fingolimod 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1 mg intravenously infused over 2 h
Study: 14705236
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 micro g/day) alone (alfacalcidol group, n = 11)
Study: 14705236
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 micro g/day) and intermittent cyclical etidronate (200 mg/day for 14 days, given for 4 cycles) (combined group, n = 10)
Study: 7665805
Drug: Bright-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright-light therapy
Study: 7665805
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light (after bright-light therapy)
Study: 7665805
Drug: Bright-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright-light therapy (control group)
Study: 30818311
Drug: Topical sialagogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sialagogue spray containing malic acid 1% (SalivAktive®)
Study: 11016777
Drug: iobitridol 300
Normalized name: iobitridol 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: iobitridol 300 (low‐osmolar, 300 mg I/ml)
Study: 11016777
Drug: iobitridol 350
Normalized name: iobitridol 350 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: iobitridol 350 (low‐osmolar, 350 mg I/ml)
Study: 11016777
Drug: ioxithalamate 350
Normalized name: meglumine ioxithalamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioxithalamate 350 (high‐osmolar, 350 mg I/ml)
Study: 6703818
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil hydrochloride (0.075 mg/kg and 0.15 mg/kg given 15 minutes apart)
Study: 6703818
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil hydrochloride
Study: 30221330
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intra-articular TXA and RIV postoperatively (Group A)
Study: 30221330
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intra-articular TXA and LMWH postoperatively (Group B)
Study: 31584145
Drug: Budesonide-formoterol (ICS-LABA)
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol (ICS-LABA) as rescue medication
Study: 31584145
Drug: ICS-LABA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS-LABA combination used as needed
Study: 31584145
Drug: Chronic ICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic ICS treatment
Study: 25740537
Drug: D2-receptor antagonist
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2-receptor antagonist amisulpride
Study: 21489663
Drug: diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet + PS (2 g/day)
Study: 18577159
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (insulin glargine) added to existing oral therapy
Study: 18577159
Drug: Rapid-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-acting insulin (insulin glulisine)
Study: 18577159
Drug: Optimization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of basal insulin dose with addition of prandial insulin
Study: 18577159
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin strategy
Study: 18577159
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin strategy
Study: 17137975
Drug: Nonventing curette
Normalized name: desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonventing curette with pump settings of 5 mL/min and 10 mm Hg
Study: 17137975
Drug: Venting curette
Normalized name: lidocaine hydrochloride Injectable Solution [Pro Vent Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venting curette with pump settings of 7 to 10 mL/min and 50 mm Hg
Study: 3305620
Drug: Chlorhexidine-fluoride gel
Normalized name: chlorhexidine / sodium fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-fluoride gel
Study: 23911560
Drug: Surgical staging
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical staging via a minimally invasive extraperitoneal approach followed by tailored radiotherapy with chemotherapy
Study: 23911560
Drug: Pelvic radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiotherapy with chemotherapy (standard-of-care arm)
Study: 11123451
Drug: Clotrimazole troche
Normalized name: Clotrimazole Troche
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole troche (10 mg, five times daily)
Study: 11123451
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (100 mg/10 mL, twice daily)
Study: 3328853
Drug: Flupirtine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (100 mg capsules and 150 mg suppositories)
Study: 2757680
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine preparation (test preparation)
Study: 2757680
Drug: Marketed reference
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed reference preparation (control)
Study: 2757680
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations (test and reference)
Study: 31758926
Drug: Monthly 0.3‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly 0.3‐mg intravitreal ranibizumab injections
Study: 29721714
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding after distal gastrectomy (DG)
Study: 29721714
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding after total gastrectomy (TG)
Study: 22658249
Drug: Sufentanil 1
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1 μg/kg plus Ropivacaine 0.5mg/kg
Study: 22658249
Drug: Sufentanil 1
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1 μg/kg, Ropivacaine 0.5mg/kg plus Epinephrine 6 μg/kg
Study: 18697911
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (HP; 3.0 g protein x kg fat‐free mass (FFM)(‐1) x day(‐1))
Study: 18697911
Drug: Usual protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual protein intake (UP; 1.5 g protein x kg FFM(‐1) x day(‐1))
Study: 9931535
Drug: Dexamethasone treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone treatment for 3 days
Study: 9931535
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 3 days
Study: 7574816
Drug: Granisetron monotherapy
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron monotherapy (40 micrograms/kg)
Study: 7574816
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus steroids (500 mg of methylprednisolone succinate or 8 mg of dexamethasone phosphate prior to granisetron)
Study: 7574816
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus steroids